Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St’s investing ideas for FREE.
AstraZeneca stock is down over the year to date but has still returned 53.6% over the past 5 years, while the latest valuation work suggests the current share price may sit well below an intrinsic value estimate. Both the Discounted Cash Flow (DCF) model and the market multiple checks indicate AstraZeneca appears undervalued at recent levels.
A 53.6% gain over 5 years indicates AstraZeneca has already created substantial shareholder value, so any current discount matters for long term investors.
Recent positive lung cancer trial results for ENHERTU and TAGRISSO based combinations can support expectations for future cash flows, while trial setbacks and ongoing legal investigations highlight the risk that some pipeline projects or assumptions may not pay off.
AstraZeneca currently passes 5 of 6 valuation checks, meaning the broader set of metrics leans cheap rather than expensive for this stock.
The key question for investors is whether that apparent discount offers a reasonable margin of safety once recent news, pipeline risks and current pricing are considered together.
Find out why AstraZeneca’s 1.9% return over the last year is lagging behind its peers.
Does AstraZeneca Look Undervalued on Cash Flow?
The Discounted Cash Flow (DCF) model values AstraZeneca based on the cash the business is expected to generate for shareholders. On this view, the company is producing solid cash generation today, with latest twelve month free cash flow of about US$7.6b and projections that assume growing cash flows rather than sharp swings. That stream of cash is converted into an estimated intrinsic value of about £231 per share.
Against the current market price, that implies the stock screens around 48.9% undervalued. The recent decision to halt the Volrustomig lung cancer trial helps explain why sentiment is cautious, even as other lung cancer drugs such as ENHERTU and TAGRISSO combinations remain in late stage development. On the DCF numbers alone, AstraZeneca appears undervalued relative to what its projected cash flows suggest.
Our Discounted Cash Flow (DCF) analysis suggests AstraZeneca is undervalued by 48.9%. Track this in your watchlist or portfolio, or discover 9 more high quality undervalued stocks.
AZN Discounted Cash Flow as at Aug 2026
Does AstraZeneca Look Undervalued on Earnings?
Story Continues
The price-to-earnings (P/E) ratio is a useful metric for AstraZeneca because earnings are a key focus for large, established pharmaceutical groups. On this measure, AstraZeneca trades on a P/E of about 23.7x, which is above the wider Pharmaceuticals industry average of 21.7x. However, it is well below the peer group average of 42.9x, which indicates a more moderate earnings valuation than some large sector peers.
The tailored fair P/E ratio for AstraZeneca is 40.5x, based on the company’s profile rather than raw sector averages. This represents a sizeable difference from the current 23.7x and indicates that the stock is pricing in a lower earnings multiple than this framework suggests would be typical for AstraZeneca today.
On the P/E multiple, AstraZeneca stock appears undervalued relative to what this earnings-based model indicates.
LSE:AZN P/E Ratio as at Aug 2026
See what the numbers say about this price — find out in our valuation breakdown.
The AstraZeneca Narrative: What Would Justify Today’s Price?
Simply Wall St Narratives for AstraZeneca link the valuation puzzle to clear stories about AstraZeneca’s future growth, margins and earnings, and explain what would need to be true for the stock to be worth materially more or less than today’s price. Each narrative ties a fair value estimate to a specific mix of potential catalysts and risks, so you can track over time which broad version of events appears to be unfolding on the Community page.
One of the top community narratives on AstraZeneca: 26% undervalued
“The company’s robust and diversified late-stage pipeline, particularly in oncology, rare diseases, and cardiovascular/metabolic therapies, is expected to deliver multiple blockbuster launches over the next several years.”
Read one of the top narratives on AstraZeneca
Do you think there’s more to the story for AstraZeneca? Head over to our Community to see what others are saying!
The Bottom Line
AstraZeneca screens as undervalued on both the Discounted Cash Flow (DCF) intrinsic value estimate and the earnings multiple view, which is a rare alignment. The wider set of valuation checks also leans supportive, so the gap between intrinsic value and the current share price looks meaningful rather than a small mispricing. The real swing factor from here is whether AstraZeneca can turn its late stage drug pipeline, including the lung cancer franchises, into durable cash flows without legal or trial setbacks eroding that thesis. The key question is whether the current discount reflects opportunity or a fair warning about those execution risks.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Companies discussed in this article include AZN.L.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com